Aeglea BioTherapeutics (AGLE) was Initiated by Needham to “Buy” and the brokerage firm has set the Price Target at $18. Needham advised their investors in a research report released on May 9, 2016.
Many Wall Street Analysts have commented on Aeglea BioTherapeutics. Aeglea BioTherapeutics was Initiated by Wells Fargo to “Outperform” on May 2, 2016.
In a different news, on Apr 12, 2016, Anthony Quinn (director) purchased 10,000 shares at $10.00 per share price. According to the SEC, on Apr 12, 2016, Russell J. Cox (director) purchased 7,000 shares at $10.00 per share price.